Absence of biallelic TCRγ deletion predicts induction failure and poorer outcomes in childhood T-cell acute lymphoblastic leukemia

Pediatric Blood and Cancer

Volumn 58, Issue 6, 2012, Pages 846-851

  Yang, Yung Li ^a,b   Hsiao, Chih Cheng ^c   Chen, Hsuan Yu ^d   Lin, Kai Hsin ^a   Jou, Shiann Tarng ^a   Chen, Jiann Shiuh ^e   Chang, Te Kau ^f   Sheen, Jiunn Ming ^c   Yu, Sung Liang ^b   Lu, Meng Yao ^a   Cheng, Chao Neng ^e   Wu, Kang Hsi ^g,h   Wang, Shih Chung ⁱ   Wang, Jiaan Der ^f   Chang, Hsiu Hao ^a   Lin, Shu Rung ^j   Lin, Shu Wha ^b   Lin, Dong Tsamn ^a  

^a NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^b NATIONAL TAIWAN UNIVERSITY   (Taiwan)

^c CHANG GUNG UNIVERSITY COLLEGE OF MEDICINE   (Taiwan)

^d INSTITUTE OF STATISTICAL SCIENCE   (Taiwan)

^e NATIONAL CHENG KUNG UNIVERSITY HOSPITAL   (Taiwan)

^f TAICHUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^g CHINA MEDICAL UNIVERSITY   (Taiwan)

^h CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

ⁱ CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^j CHUNG YUAN CHRISTIAN UNIVERSITY   (Taiwan)

more..

Author keywords

Absence of TCR deletion; Childhood T cell ALL

Indexed keywords

DEXAMETHASONE; DNA POLYMERASE; PREDNISOLONE; T LYMPHOCYTE RECEPTOR GAMMA CHAIN;

ACUTE LYMPHOBLASTIC LEUKEMIA; AGE; ARTICLE; CANCER CHEMOTHERAPY; CANCER INCIDENCE; CANCER PATIENT; CANCER SURVIVAL; CHILD; CHILDHOOD LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE REDUCTION; FEMALE; GENE DELETION; HOMOZYGOUS DELETION; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; LEUKOCYTE COUNT; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; QUANTITATIVE ANALYSIS; SCHOOL CHILD; T CELL LEUKEMIA; TAIWAN;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; GENE DELETION; GENES, T-CELL RECEPTOR GAMMA; HUMANS; IMMUNOPHENOTYPING; INDUCTION CHEMOTHERAPY; KAPLAN-MEIER ESTIMATE; POLYMERASE CHAIN REACTION; PRECURSOR T-CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TREATMENT OUTCOME;

EID: 84863353013     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24021     Document Type: Article

References (45)

1. Jeha S, Pui CH. Risk-adapted treatment of pediatric acute lymphoblastic leukemia. Hematol Oncol Clin North Am 2009; 23: 973-990 v.
2. Pui CH, Carroll WL, Meshinchi S, et al. Biology, risk stratification, and therapy of pediatric acute leukemias: An update. J Clin Oncol 2011; 29: 551-565.
3. Escherich G, Horstmann MA, Zimmermann M, et al. Cooperative study group for childhood acute lymphoblastic leukaemia (COALL): Long-term results of trials 82, 85, 89, 92 and 97. Leukemia 2010; 24: 298-308.
4. Conter V, Arico M, Basso G, et al. Long-term results of the Italian Association of Pediatric Hematology and Oncology (AIEOP) studies 82, 87 88, 91 and 95 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 255-264.
5. Gaynon PS, Angiolillo AL, Carroll WL, et al. Long-term results of the children's cancer group studies for childhood acute lymphoblastic leukemia 1983-2002: A Children's Oncology Group report. Leukemia 2010; 24: 285-297.
6. Kamps WA, van der Pal-de Bruin KM, Veerman AJP, et al. Long-term results of Dutch Childhood Oncology Group studies for children with acute lymphoblastic leukemia from 1984 to 2004. Leukemia 2010; 24: 309-319.
7. Liang DC, Yang CP, Lin DT, et al. Long-term results of Taiwan Pediatric Oncology Group studies 1997 and 2002 for childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 397-405.
8. Mitchell C, Richards S, Harrison CJ, et al. Long-term follow-up of the United Kingdom medical research council protocols for childhood acute lymphoblastic leukaemia, 1980-2001. Leukemia 2010; 24: 406-418.
9. Moricke A, Zimmermann M, Reiter A, et al. Long-term results of five consecutive trials in childhood acute lymphoblastic leukemia performed by the ALL-BFM study group from 1981 to 2000. Leukemia 2010; 24: 265-284.
10. Tsurusawa M, Shimomura Y, Asami K, et al. Long-term results of the Japanese Childhood Cancer and Leukemia study group studies 811, 841 874 and 911 on childhood acute lymphoblastic leukemia. Leukemia 2010; 24: 335-344.
11. Tsuchida M, Ohara A, Manabe A, et al. Long-term results of Tokyo Children's Cancer Study Group trials for childhood acute lymphoblastic leukemia, 1984-1999. Leukemia 2010; 24: 383-396.
12. Silverman LB, Stevenson KE, O'Brien JE, et al. Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985-2000). Leukemia 2010; 24: 320-334.
13. Stark B, Nirel R, Avrahami G, et al. Long-term results of the Israeli National Studies in childhood acute lymphoblastic leukemia: Ins 84, 89 and 98. Leukemia 2010; 24: 419-424.
14. Stary J, Jabali Y, Trka J, et al. Long-term results of treatment of childhood acute lymphoblastic leukemia in the Czech Republic. Leukemia 2010; 24: 425-428.
15. Pui CH, Campana D, Pei D, et al. Treating childhood acute lymphoblastic leukemia without cranial irradiation. N Engl J Med 2009; 360: 2730-2741.
16. Pui CH, Evans WE. Treatment of acute lymphoblastic leukemia. N Engl J Med 2006; 354: 166-178.
17. Pui CH, Robison LL, Look AT. Acute lymphoblastic leukaemia. Lancet 2008; 371: 1030-1043.
18. Pullen J, Shuster JJ, Link M, et al. Significance of commonly used prognostic factors differs for children with T cell acute lymphocytic leukemia (ALL), as compared to those with B-precursor all. A Pediatric Oncology Group (POG) study. Leukemia 1999; 13: 1696-1707.
19. Ferrando AA, Neuberg DS, Staunton J, et al. Gene expression signatures define novel oncogenic pathways in T cell acute lymphoblastic leukemia. Cancer Cell 2002; 1: 75-87.
20. van Grotel M, Meijerink JPP, van Wering ER, et al. Prognostic significance of molecular-cytogenetic abnormalities in pediatric T-ALL is not explained by immunophenotypic differences. Leukemia 2007; 22: 124-131.
21. Cleaver AL, Beesley AH, Firth MJ, et al. Gene-based outcome prediction in multiple cohorts of pediatric T-cell acute lymphoblastic leukemia: A children's oncology group study. Mol Cancer 2010; 9: 105.
22. Winter SS, Jiang Z, Khawaja HM, et al. Identification of genomic classifiers that distinguish induction failure in T-lineage acute lymphoblastic leukemia: A report from the Children's Oncology Group. Blood 2007; 110: 1429-1438.
23. Attarbaschi A, Pisecker M, Inthal A, et al. Prognostic relevance of TLX3 (HOX11L2)expression in childhood t-cell acute lymphoblastic leukaemia treated with Berlin-Frankfurt-Munster (BFM) protocols containing early and late re-intensification elements. Br J Haematol 2010; 148: 293-300.
24. Gutierrez A, Sanda T, Ma W, et al. Inactivation of LEF1 in T-cell acute lymphoblastic leukemia. Blood 2010; 115: 2845-2851.
25. Larson Gedman A, Chen Q, Kugel Desmoulin S, et al. The impact of NOTCH1, FBW7 and PTEN mutations on prognosis and downstream signaling in pediatric T-cell acute lymphoblastic leukemia: A report from the Children's Oncology Group. Leukemia 2009; 23: 1417-1425.
26. Van Vlierberghe P, Palomero T, Khiabanian H, et al. PHF6 mutations in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42: 338-342.
27. Heesch S, Goekbuget N, Stroux A, et al. Prognostic implications of mutations and expression of the Wilms Tumor 1 (WT1) gene in adult acute T-lymphoblastic leukemia. Haematologica 2010; 95: 942-949.
28. Tosello V, Mansour MR, Barnes K, et al. WT1 mutations in T-all. Blood 2009; 114: 1038-1045.
29. Weng AP. Activating mutations of NOTCH1 in human T cell acute lymphoblastic leukemia. Science 2004; 306: 269-271.
30. Kleppe M, Lahortiga I, El Chaar T, et al. Deletion of the protein tyrosine phosphatase gene PTPN2 in T-cell acute lymphoblastic leukemia. Nat Genet 2010; 42: 530-535.
31. Kox C, Zimmermann M, Stanulla M, et al. The favorable effect of activating NOTCH1 receptor mutations on long-term outcome in T-all patients treated on the ALL-BFM 2000 protocol can be separated from FBXW7 loss of function. Leukemia 2010; 24: 2005-2013.
32. Clappier E, Collette S, Grardel N, et al. NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951. Leukemia 2010; 24: 2023-2031.
33. Ferrando A. NOTCH mutations as prognostic markers in T-ALL. Leukemia 2010; 24: 2003-2004.
34. Zuurbier L, Homminga I, Calvert V, et al. NOTCH1 and/or FBWX7 mutations predict for initial good prednisone response but not for improved outcome in pediatric T-cell acute lymphoblastic leukemia patients treated on DCOG or COALL protocols. Leukemia 2010; 24: 2014-2022.
35. Coustan-Smith E, Mullighan CG, Onciu M, et al. Early T-cell precursor leukaemia: A subtype of very high-risk acute lymphoblastic leukaemia. Lancet Oncol 2009; 10: 147-156.
36. Gutierrez A, Dahlberg SE, Neuberg DS, et al. Absence of biallelic TCRgamma deletion predicts early treatment failure in pediatric T-cell acute lymphoblastic leukemia. J Clin Oncol 2010; 28: 3816-3823.
37. Yang YL, Lin DT, Chang SK, et al. Pharmacogenomic variations in treatment protocols for childhood acute lymphoblastic leukemia. Pediatr Blood Cancer 2010; 54: 206-211.
38. Goldberg JM. Childhood T-cell acute lymphoblastic leukemia: The Dana-Farber Cancer Institute acute lymphoblastic leukemia consortium experience. J Clin Oncol 2003; 21: 3616-3622.
39. Basso G, Veltroni M, Valsecchi MG, et al. Risk of relapse of childhood acute lymphoblastic leukemia is predicted by flow cytometric measurement of residual disease on day 15 bone marrow. J Clin Oncol 2009; 27: 5168-5174.
40. Mullighan CG, Goorha S, Radtke I, et al. Genome-wide analysis of genetic alterations in acute lymphoblastic leukaemia. Nature 2007; 446: 758-764.
41. Georgopoulos K. Acute lymphoblastic leukemia-On the wings of Ikaros. N Engl J Med 2009; 360: 524-526.
42. Mullighan CG, Su X, Zhang J, et al. Deletion of IKZF1 and prognosis in acute lymphoblastic leukemia. N Engl J Med 2009; 360: 470-480.
43. Waanders E, van der Velden VHJ, van der Schoot CE, et al. Integrated use of minimal residual disease classification and IKZF1 alteration status accurately predicts 79% of relapses in pediatric acute lymphoblastic leukemia. Leukemia 2011; 25: 254-258.
44. Yang YL, Hung CC, Chen JS, et al. IKZF1 deletions predict a poor prognosis in children with B-cell progenitor acute lymphoblastic leukemia: A multicenter analysis inTaiwan. Cancer Sci 2011; 102: 1874-1881.
45. Martinelli G, Iacobucci I, Storlazzi CT, et al. IKZF1 (Ikaros) deletions in BCR-ABL1-positive acute lymphoblastic leukemia are associated with short disease-free survival and high rate of cumulative incidence of relapse: A GIMEMA AL WP report. J Clin Oncol 2009; 27: 5202-5207.